Concepedia
Statistics
Publications
5
Citations
301
H-Index
Active since
1979
Affiliations
Washington University in St. Louis(Current)
GlaxoSmithKline (Brazil)
GlaxoSmithKline (United Kingdom)
GlaxoSmithKline (United States)
The Ohio State University
Mark Whitaker is an author at Washington University in St. Louis specializing in pharmacology, medicine, and bioavailability.
Publications per year
1979–2022
Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: Pharmacological basis for a therapeutic approach
Philip Needleman, Mark Whitaker, Angela Wyche et al. · Prostaglandins · 1980 · 130 citations
Medicine, Biochemistry, Pharmacology +17
Triene prostaglandins: Prostaglandin D <sub>3</sub> and icosapentaenoic acid as potential antithrombotic substances
Mark Whitaker, Angela Wyche, F.A. Fitzpatrick et al. · Proceedings of the National Academy of Sciences · 1979 · 123 citations · Full text
A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties
Neil Moss, Younggi Choi, Derek A. Cogan et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 25 citations · Full text
Medicine, Pharmacokinetics, Pharmacology +11
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
Debra Tompson, Mark Whitaker, Rennan Pan et al. · Pharmaceutical Research · 2022 · 12 citations · Full text
Pharmacy, Pharmacokinetics, Pharmacology +16
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
Debra Tompson, Mark Whitaker, Rennan Pan et al. · Pharmaceutical Research · 2021 · 11 citations · Full text
Pharmacy, Pharmaceutics, Pharmacology +15
1–5 of 5